Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 171 AML: cobicistat-boosted venetoclax plus azacitidine in newly diagnosed AML unfit for intensive therapy
2023-505379-61-00Phase 2Suspended
- Sponsor
- HOVON
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, cobicistat and azacitidine in acute myeloid leukemia (AML), sponsored by HOVON. Primary endpoints: Pharmacokinetic equivalence and Overall survival. Started Jan 2024; status: suspended.
02
Drugs
venetoclaxcobicistatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-505379-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505379-61-00.